Insights

Cell and Gene Therapy

Cell and Gene Therapy

Treatment of chronic conditions is the new frontier for stem cell-derived therapies: Deep phenotyping and manufacturing scale-up key to opening clinic doors, say experts at TTP’s panel discussion

cancer cells being attacked by T Cells

Cell and Gene Therapy

With personalised cancer vaccines on the rise, is manufacturing scalable yet?

How is cell and gene therapy innovation adapting to a changing investment landscape? Insights from TTP’s Cell & Gene panel event

How can you prove 99.9% reliability? A challenge in automating and scaling cell therapies

What failure rate are we willing to accept in cell therapy manufacture? Insights from medical device development

Special Delivery: can advanced intracellular delivery enable superior cell therapies for solid tumour treatment – and beyond?

Only a ‘click’ away: click chemistry transforms life science applications

Driving Cell Therapy Innovation: Applying Key Lessons from the Evolution and Commercialization of Protein-Based Therapies

Predicting failure rates in cell therapy manufacturing: is one in a million good enough?

How many cells should a therapeutic cell sorter sort? (Part 3)

Who should lead the charge in cell therapy manufacturing?

How many cells should a therapeutic cell sorter sort? (Part 2)

How many cells should a therapeutic cell sorter sort? (Part 1)

Why does cell therapy need a better cell sorter?